learningandfinance.com


Business

Dr Reddy's hits fresh 52-week low after patent infringement confirmation

Share

Dr Reddy's said it did not infringe three of the claims, adding that the remaining ten were invalid but that it would have infringed them should they be found valid.

City-based drug giant Dr Reddy's Laboratories (DRL) on Thursday informed the bourses that it has received an unfavourable ruling in a patent infringement case related to Palonosetron Hydrochloride 0.25mg/5ml, Swiss player Helsinn Healthcare's nausea prevention drug Aloxi.

Dr Reddy's Laboratories yesterday said it has received an unfavourable ruling in a United States court regarding a patent infringement case over Aloxi.

Google CEO responds to 7-year-old who wants job
I'm glad that you like computers and robots, and hope that you will continue to learn about technology. Chloe unexpectedly agreed, and pulled out a sheet of notebook paper to jot down her ideas.

Tony Blair calls for people to 'rise up' against Brexit
He will criticise Theresa May by saying she is leading a "mono-purpose" Government "for Brexit, of Brexit and dominated by Brexit".

Five-star Bayern Munich thrash Arsenal as Real Madrid put three past Napoli
Bayern put gloss on their performance as Thomas Muller, fresh onto the field as a substitute, applied a cool finish past Ospina. His post-match press conference lasted barely five minutes and was cut short after he answered just a few questions.

Aloxi injection is used in adults to help prevent nausea and vomiting due to chemotherapy.

The district court said in its ruling: "We find that the asserted claims in the '724, '094, and '980 patents are infringed".

The company said it intends to pursue an appeal in due course of time. The settlement will allow it to market the generic version of Aloxi in the USA on September 30, 2018, or earlier, under certain circumstances. The approval came after DRL entered into a settlement agreement with Swiss pharma player Helsinn Healthcare SA in October 2015 to resolve patent litigations relating to Aloxi in the US. The company would have had to do its own branding and marketing to sell the drug, Surajit Pal, an analyst with Mumbai-based brokerage Prabhudas Lilladher told CNBC-TV18. The other generics will enter the market in September 2018, which would have provided Dr Reddy's with one-and-a-half years of headstart to capture a good share of the market. On NSE, it fell by 3.86% to Rs2,798.95-its 52-week low. Benchmark BSE Sensex was trading 37.63 points, or 0.13 per cent up at 28,193.19.

Share